Research Lung Cancer Decision-Making Support

AI-Driven Multiagent System for Guiding First-Line Immunotherapy for NSCLC

A multi-agent system demonstrated correct and complete reasoning in determining the use of immunotherapy for patients with non–small cell lung cancer (NSCLC) in the first-line setting.

February 23, 2026 By Lisa Astor 5 min read
Share

0 Key Takeaways

ASCO AI in Oncology is published by Conexiant under a license arrangement with the American Society of Clinical Oncology, Inc. (ASCO®). The ideas and opinions expressed in ASCO AI in Oncology do not necessarily reflect those of Conexiant or ASCO. For more information, see Policies.

KOL Commentary
Watch

Related Content